Who
Frank Morich
Director
Company insider
Files Form 4 as: Director, Perspective Therapeutics; Director, Cue Biopharma.
In numbers
- Trades disclosed
- 19
- Buys
- 1
- Sells
- 0
- Bought
- $105K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 31 Jul 2018
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 12 Dec 2023filed 14 Dec 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —470,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 May 2022filed 31 May 2022 | CUE Cue BiopharmaBiotechnology | SEC FORM 4 Bought | $105K28,000 at $3.75 | filing |
| 3 Jan 2022filed 5 Jan 2022 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 May 2020filed 12 May 2020 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,200 at $0.00 | filing |
| 2 Jan 2020filed 6 Jan 2020 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 2 Jan 2019filed 3 Jan 2019 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 31 Jul 2018filed 2 Aug 2018 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Cue Biopharma (NASDAQ:CUE) Stock: Insider Michael Vincent Meluzio Sells 1,144 SharesCUE · dailypolitical.com · 15 Oct 2026Cue Biopharma (NASDAQ:CUE) Insider Sells $51,724.20 in StockCUE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Frank Morich; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.